Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 2/10/2019

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Table 15c. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects  
( Last updated May 22, 2018; last reviewed May 22, 2018)  
(page 1 of 2)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Associated ARVs</th>
<th>Onset/Clinical Manifestations</th>
<th>Estimated Frequency</th>
<th>Risk Factors</th>
<th>Prevention/Monitoring</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea/Vomiting</td>
<td>All ARVs, but most notably—NRTIs: • ddI and ZDV at a higher rate than others PIs: • Especially with RTV boosting (e.g., LPV/r, DRV/r)</td>
<td>Onset: • Early Presentation: • Nausea, emesis—may be associated with anorexia and/or abdominal pain</td>
<td>Varies with ARV agent; 10% to 30% in some series</td>
<td>Unknown</td>
<td>Instruct patient to take PIs with food. Monitor for weight loss, ARV adherence. Do not use ddI, d4T, or NFV (individually or together) as part of an ARV regimen.</td>
<td>Reassure patient that these adverse effects generally improve over time (usually 6–8 weeks). Supportive care. In extreme or persistent cases, use antiemetics or switch ARV regimen.</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>PIs: • Particularly NFV, LPV/r, and DRV/r NRTIs: • ddI and d4T at a higher rate than 3TC or FTC</td>
<td>Onset: • Early Presentation: • Generally soft, more frequent stools</td>
<td>Varies with ARV agent; generally ≤15% (range 5% to 30%)</td>
<td>Unknown</td>
<td>Monitor for weight loss, dehydration. Do not use ddI, d4T, or NFV (individually or together) as part of an ARV regimen.</td>
<td>If prolonged or severe, exclude infectious or noninfectious (e.g., lactose intolerance) causes of diarrhea. Reassure patient that this adverse effect generally improves over time (usually 6–8 weeks). Consider switching ARV regimen in persistent and severe cases. Although treatment data in children are lacking, potentially useful modalities include: • Dietary modification • Bulk-forming agents (psyllium) • Antimotility agents (loperamide) • Crofelemer is FDA-approved for treatment of ART-associated diarrhea only in adults ≥18 years of age; no pediatric data available.</td>
</tr>
</tbody>
</table>
Table 15c. Antiretroviral-Therapy-Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects (Last updated May 22, 2018; last reviewed May 22, 2018) (page 2 of 2)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Associated ARVs</th>
<th>Onset/Clinical Manifestations</th>
<th>Estimated Frequency</th>
<th>Risk Factors</th>
<th>Prevention/Monitoring</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatitis</td>
<td>ddI, d4T, and NFV</td>
<td>Onset: Anytime, usually after months of therapy</td>
<td>&lt;2% in recent series</td>
<td>Use of concomitant medications associated with pancreatitis (e.g., TMP-SMX, pentamidine, ribavirin)</td>
<td>Do not use ddI or d4T (individually or together) as part of an ARV regimen.</td>
<td>Discontinue offending agent—avoid reintroduction. Manage symptoms of acute episode. If associated with hypertriglyceridemia, consider interventions to lower TG levels.</td>
</tr>
</tbody>
</table>

Key to Acronyms: 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; d4T = stavudine; ddI = didanosine; DRV/r = darunavir/ritonavir; FDA = Food and Drug Administration; FTC = emtricitabine; LPV/r = lopinavir/ritonavir; NFV = nelfinavir; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; RTV = ritonavir; TG = triglyceride; TMP-SMX = trimethoprim sulfamethoxazole; ZDV = zidovudine

References


